Esmirtazapine + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sleep Initiation and Maintenance Disorders
Conditions
Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias, Sleep Disorders, Sleep Disorder, Intrinsic
Trial Timeline
Mar 4, 2008 → Nov 19, 2009
NCT ID
NCT00631657About Esmirtazapine + Placebo
Esmirtazapine + Placebo is a phase 3 stage product being developed by Merck for Sleep Initiation and Maintenance Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00631657. Target conditions include Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00631657 | Phase 3 | Completed |
| NCT00561821 | Phase 3 | Completed |
| NCT00506389 | Phase 3 | Completed |
| NCT00482612 | Phase 3 | Completed |
| NCT00560833 | Phase 3 | Completed |
| NCT00535288 | Phase 3 | Completed |
Competing Products
20 competing products in Sleep Initiation and Maintenance Disorders